Here, we demonstrate that melanoma cells resistant to MAPK inhibitors rewire glucose metabolism and activate integrated NRF2-dependent antioxidant responses for protection against oxidative stress (Fig. 5). The gene discussed is NFE2L2; the disease is melanoma.